Arrowhead’s bid to become a large-cap biotech

As it embarks on its first commercial launch, Arrowhead Pharmaceuticals believes it has built the pipeline and enabling technologies needed to enter a steep period of value creation. It only took 20 years to get here.

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) spent its first decade evolving from a nanotechnology company into an RNAi-focused biotech. It spent the next refining its platform to compete clinically and commercially...